Expression of a chimeric antigen receptor in multiple leukocyte lineages in transgenic mice

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Yong, Carmen S M ^a   Westwood, Jennifer A ^a   Schröder, Jan ^a,b,c   Papenfuss, Anthony T ^a,b,c   Von Scheidt, Bianca ^a   Moeller, Maria ^a   Devaud, Christel ^a,d   Darcy, Phillip K ^a,e   Kershaw, Michael H ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d INSERM   (France)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; TUMOR ANTIGEN; RECOVERIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; GENE SEQUENCE; IMMUNOPHENOTYPING; LEUKOCYTE; LYMPH NODE; LYMPHOCYTE; LYMPHOID CELL; LYMPHOID ORGAN; MACROPHAGE; MOUSE; MOUSE MODEL; MOUSE STRAIN; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SPLEEN CELL; SPLEEN LYMPHOCYTE; T LYMPHOCYTE; THYMOCYTE; THYMUS; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; CELL LINEAGE; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, TRANSGENIC; NEOPLASMS; RECOVERIN; SIGNAL TRANSDUCTION; THYMOCYTES; THYMUS GLAND;

EID: 84949595531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140543     Document Type: Article

References (67)

1. Lahl K, Sparwasser T. In vivo depletion of FoxP3+Tregs using the DEREG mouse model. Methods in molecular biology (Clifton, NJ). 2011; 707:157-72.
2. Hogquist KA, Jameson SC, Heath W.R., Howard JL, Bevan MJ, Carbone FR. Tcell receptor antagonist peptides induce positive selection. Cell. 1994 Jan 14; 76(1):17-27. PMID: 8287475
3. Morgan DJ, Liblau R, Scott B., Fleck S, McDevitt HO, Sarvetnick N, et al. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol. 1996 Aug1; 157(3):978-83. PMID: 8757600
4. Turner M, Billadeau DD Vav proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol. 2002 Jul; 2(7):476-86. PMID: 12094222
5. Ogilvy S, Metcalf D, Gibson L., Bath ML, Harris AW, Adams JM. Promoter elements of vav drive trans-gene expression in vivo throughout the hematopoietic compartment. Blood. 1999 Sep 15; 94(6):1855-63. PMID: 10477714
6. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998 Jan 15; 91(2):419-30. PMID: 9427694
7. Restifo NP, Dudley ME, Rosenberg SA Adoptive immunotherapy for cancer: harnessing the T cell response. Nature reviews Immunology. 2012 Apr; 12(4):269-81. doi: 10.1038/nri3191 PMID: 22437939
8. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18; 198(4):569-80. PMID: 12925674
9. Klebanoff CA, Gattinoni L, Palmer D.C., Muranski P., Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011 Aug 15; 17(16):5343-52.
10. Maude SL, Frey N, Shaw P.A., Aplenc R., Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England journal of medicine. 2014 Oct 16; 371 (16):1507-17. doi: 10.1056/NEJMoa1407222 PMID: 25317870
11. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014 Aug 25.
12. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CART cell therapy in Bcell acute lymphoblastic leukemia. Science translational medicine. 2014 Feb 19; 6(224):224ra25. doi: 10.1126/scitranslmed.3008226 PMID: 24553386
13. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med. 2010 Oct 25; 207 (11):2469-77. doi: 10.1084/jem.20092450 PMID: 20921286
14. Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, et al. Both CD4and CD8TCells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase. The Journal of Immunology. 2010 June 1, 2010; 184(11):5988-98. doi: 10.4049/jimmunol.1000189 PMID: 20427771
15. Klug F, Prakash H, Huber P.E., Seibel T., Bender N, Halama N, et al Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer cell. 2013 Nov 11; 24(5):589-602. doi: 10.1016/j.ccr.2013.09.014 PMID: 24209604
16. Lu Y, Hong B, Li H., Zheng Y, Zhang M, Wang S., et al. Tumor-specificIL-9-producingCD8+Tc9 cells are superior effectorthan type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A. 2014 Feb 11; 111(6):2265-70. doi: 10.1073/pnas.1317431111 PMID: 24469818
17. Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MW, Street SE, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood. 2005 Nov 1; 106(9):2995-3003. PMID: 16030195
18. Turner M, Mee PJ, Walters A.E., Quinn ME, Mellor AL, Zamoyska R, et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity. 1997 Oct; 7(4):451-60. PMID: 9354466
19. Saveliev A, Vanes L, Ksionda O, Rapley J, Smerdon SJ, Rittinger K, et al. Function of the nucleotide exchange activity of vav1 in T cell development and activation. Sci Signal. 2009; 2(101):ra83. doi: 10.1126/scisignal.2000420 PMID: 20009105
20. Chan G, Hanke T, Fischer K-D. Vav-1 regulates NKT cell development and NK cell cytotoxicity. European Journal of Immunology. 2001; 31(8):2403-10. PMID: 11500824
21. John LB, Devaud C, Duong C.P., Yong CS, Beavis PA, Haynes NM, et al Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013 Oct 15; 19 (20):5636-46.
22. Ogilvy S, Metcalf D, Print C.G., Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. PNAS. 1999 Dec 21; 96(26):14943-8. PMID: 10611317
23. Slater GS, Birney E. Automated generation of heuristics for biological sequence comparison. BMC bio-informatics. 2005; 6:31. PMID: 15713233
24. Schroder J, Hsu A, Boyle S.E., Macintyre G, Cmero M, Tothill RW, et al. Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics (Oxford, England). 2014 Jan 22.
25. Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (Oxford, England). 2012 Feb 1; 28(3):423-5.
26. Williams AL, Bielopolski N, Meroz D., Lam AD, Passmore DR, Ben-Tal N, et al. Structural and functional analysis of tomosyn identifies domains important in exocytotic regulation. The Journal of biological chemistry. 2011 Apr 22; 286(16):14542-53. doi: 10.1074/jbc.M110.215624 PMID: 21330375
27. Bhatnagar S, Oler AT, Rabaglia ME, Stapleton DS, Schueler KL, Truchan NA, et al. Positional cloning of a type 2 diabetes quantitative trait locus; tomosyn-2, a negative regulator of insulin secretion. PLoS genetics. 2011 Oct; 7(10):e1002323. doi: 10.1371/journal.pgen.1002323 PMID: 21998599
28. Geerts CJ, Plomp JJ, Koopmans B, Loos M, van der Pijl EM, van der Valk MA, et al. Tomosyn-2 is required for normal motor performance in mice and sustains neurotransmission at motor endplates. Brain structure & function. 2014 Apr 18.
29. Bhatnagar S, Soni MS, Wrighton LS, Hebert AS, Zhou AS, Paul PK, et al. Phosphorylation and Degradation of Tomosyn-2 De-represses Insulin Secretion. Journal of Biological Chemistry. 2014 September 5, 2014; 289(36):25276-86. doi: 10.1074/jbc.M114.575985 PMID: 25002582
30. Fischer KD, Zmuldzinas A, Gardner S., Barbacid M, Bernstein A, Guidos C. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+CD8+thymocytes. Nature. 1995 Mar 30; 374 (6521):474-7. PMID: 7700360
31. Bustelo XR, Ledbetter JA, Barbacid M. Product of vavproto-oncogene defines a new class of tyrosine protein kinase substrates. Nature. 1992 Mar 5; 356 (6364):68-71. PMID: 1311423
32. Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, et al. Tyrosine phosphorylation of vavproto-oncogene product containing SH2 domain and transcription factor motifs. Nature. 1992 Mar 5; 356 (6364):71-4. PMID: 1531699
33. Folger KR, Wong EA, Wahl G, Capecchi MR Patterns of integration of DNA microinjected into cultured mammalian cells: evidence for homologous recombination between injected plasmid DNA molecules. Molecular and cellular biology. 1982 Nov; 2(11):1372-87. PMID: 6298598
34. Chen ZY, Yant SR, He C.Y., Meuse L., Shen S, Kay MA. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. MolTher. 2001 Mar; 3(3):403-10. PMID: 11273783
35. Yan B, Li D, Gou K. Homologous illegitimate random integration of foreign DNA into the X chromosome of a transgenic mouse line. BMC molecular biology. 2010; 11:58. doi: 10.1186/1471-2199-11-58 PMID: 20707910
36. Hamada T, Sasaki H, Seki R, Sakaki Y. Mechanism of chromosomal integration of transgenes in micro-injected mouse eggs: sequence analysis of genome-transgene and transgene-transgene junctions at two loci. Gene. 1993 Jun 30; 128(2):197-202. PMID: 8390388
37. Bishop JO, Smith P. Mechanism of chromosomal integration of microinjected DNA. Molecular biology & medicine. 1989 Aug; 6(4):283-98.
38. Brinster RL, Chen HY, Trumbauer M, Senear A.W., Warren R., Palmiter RD. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell. 1981 Nov; 27(1 Pt 2):223-31. PMID: 6276022
39. Singer T, Burke E. High-throughput TAIL-PCR as atool to identify DNA flanking insertions. Methods in molecular biology (Clifton, NJ). 2003; 236:241-72.
40. Colucci F, Rosmaraki E, Bregenholt S., Samson SI, Di Bartolo V, Turner M, et al Functional Dichotomy in Natural Killer Cell Signaling: Vav1-Dependent and - Independent Mechanisms. The Journal of Experimental Medicine. 2001 June 18, 2001; 193(12):1413-24. PMID: 11413196
41. Zhang R, Alt FW, Davidson L, Orkin S.H., Swat W. Defective signalling through the T-and B-cell antigen receptors in lymphoid cells lacking the vavproto-oncogene. Nature. 1995 Mar 30; 374 (6521):470-3. PMID: 7700359
42. Hall AB, Gakidis MA, Glogauer M, Wilsbacher J.L., Gao S., Swat W, et al. Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis. Immunity. 2006 Mar; 24(3):305-16. PMID: 16546099
43. Wells CM, Bhavsar PJ, Evans I.R., Vigorito E., Turner M, Tybulewicz V, et al. Vav1 and Vav2 play different roles in macrophage migration and cytoskeletal organization. Experimental cell research. 2005 Nov 1; 310(2):303-10. PMID: 16137676
44. Bhavsar PJ, Vigorito E, Turner M., Ridley AJ. Vav GEFs regulate macrophage morphology and adhesion-induced Rac and Rho activation. Experimental cell research. 2009 Nov 15; 315(19):3345-58. doi: 10.1016/j.yexcr.2009.08.010 PMID: 19715691
45. Gakidis MA, Cullere X, Olson T, Wilsbacher JL, Zhang B, Moores SL, et al. Vav GEFs are required for beta2 integrin-dependent functions of neutrophils. The Journal of cell biology. 2004 Jul 19; 166(2):273-82. PMID: 15249579
46. Fujikawa K, Miletic AV, Alt FW, Faccio R, Brown T, Hoog J, et al. Vav1/2/3-null Mice Define an Essential Role for Vav Family Proteins in Lymphocyte Development and Activation but a Differential Requirement in MAPK Signaling in Tand B Cells. The Journal of Experimental Medicine. 2003 November 17, 2003; 198(10):1595-608. PMID: 14623913
47. Zmuidzinas A, Fischer KD, Lira S.A., Forrester L., Bryant S, Bernstein A, et al Thevavproto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. The EMBO journal. 1995 Jan 3; 14(1):1-11. PMID: 7828581
48. Raberger J, Boucheron N, Sakaguchi S., Penninger JM, Ellmeier W. Impaired T-cell development in the absence of Vav1 and Itk. European Journal of Immunology. 2008; 38(12):3530-42. doi: 10.1002/eji.200838388 PMID: 19009524
49. Tarakhovsky A, Turner M, Schaal S., Mee PJ, Duddy LP, Rajewsky K, et al Defective antigen receptor-mediated proliferation of Band T cells in the absence of Vav. Nature. 1995 Mar 30; 374 (6521):467-70. PMID: 7700358
50. Bustelo XR. Regulatory and signaling properties of the Vav family. Molecular and cellular biology. 2000 Mar; 20(5):1461-77. PMID: 10669724
51. Fischer KD, Kong YY, Nishina H, Tedford K., Marengere LE, Kozieradzki I, et al. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Current biology: CB. 1998 May 7; 8 (10):554-62. PMID: 9601639
52. Zhang W, Sommers CL, Burshtyn D.N., Stebbins CC, DeJarnette JB, Trible RP, et al. Essential role of LAT in T cell development. Immunity. 1999 Mar; 10(3):323-32. PMID: 10204488
53. Pivniouk V, Tsitsikov E, Swinton P, Rathbun G., Alt FW, Geha RS. Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76. Cell. 1998 Jul 24; 94(2):229-38. PMID: 9695951
54. Chu DH, Morita CT, Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunological reviews. 1998 Oct; 165:167-80. PMID: 9850860
55. Gilfillan S, Aiso S, Michie S.A., McDevitt HO. Immune deficiency due to high copy numbers of an Ak beta transgene. Proc Natl Acad Sci USA. 1990 Sep; 87(18):7319-23. PMID: 2119506
56. Singer SM, Umetsu DT, McDevitt HO High copy number I-Ab transgenes induce production of IgE through an interluekin 4-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America. 1996 Apr 2; 93(7):2947-52. PMID: 8610148
57. Wang B, Biron C, She J, Higgins K, Sunshine MJ, Lacy E, et al. A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3E gene. Proceedings of the National Academy of Sciences of the United States of America. 1994 Sep 27; 91 (20):9402-6. PMID: 7937778
58. Lacorazza HD, Porritt HE, Nikolich-Zugich J. Dysregulated expression of pre-Talpha reveals the opposite effects of pre-TCR at successive stages of T cell development. J Immunol. 2001 Nov 15; 167 (10):5689-96. PMID: 11698441
59. DeFranco AL. Vav and the Bcell signalosome. Nature immunology. 2001 Jun; 2(6):482-4. PMID: 11376331
60. Corre I, Gomez M, Vielkind S., Cantrell DA. Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. J Exp Med. 2001 Oct 1; 194 (7):903-14. PMID: 11581313
61. Godfrey DI, Hammond KJ, Poulton L.D., Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunology today. 2000 Nov; 21(11):573-83. PMID: 11094262
62. Le Bourhis L., Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O. Mucosal-associated invariant T cells: unconventional development and function. Trends in immunology. 2011 May; 32(5):212-8. doi: 10.1016/j.it.2011.02.005 PMID: 21459674
63. Walker JA, Barlow JL, McKenzie AN Innate lymphoid cells - how did we miss them? Nat Rev Immunol. 2013 Feb; 13(2):75-87. doi: 10.1038/nri3349 PMID: 23292121
64. Darcy PK, Haynes NM, Snook M.B., Trapani JA, Cerruti L, Jane SM, et al Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL. The Journal of Immunology. 2000 April 1,2000; 164(7):3705-12. PMID: 10725729
65. Haynes NM, Snook MB, Trapani J.A., Cerruti L., Jane SM, Smyth MJ, et al. Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-Çvs FcsRI-y. The Journal of Immunology. 2001 January 1, 2001; 166(1):182-7. PMID: 11123291
66. Piechocki MP, Ho YS, Pilon S, Wei WZ Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. Journal of immunology (Baltimore, Md: 1950). 2003 Dec 1; 171 (11):5787-94.
67. Langmead B, Trapnell C, Pop M., Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome biology. 2009; 10(3):R25. doi: 10.1186/gb-2009-10-3-r25 PMID: 19261174